Search

Displaying results 4881 - 4890 of 7283 in total
  1. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules. … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase

  2. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).

  3. Drug

    Estetrol

    go.drugbank.com/drugs/DB12235
    ApprovedInvestigational

    The combination of drospirenone and estetrol offers a new choice with a favourable safety profile for women seeking contraceptive therapy. … [L33184] Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception.

  4. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. … [L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued

  5. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5. … [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]

  6. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen. … Multiple myeloma is a cancer where plasma cells rapidly divide out of control.

  7. Drug

    Atorvastatin

    go.drugbank.com/drugs/DB01076
    ApprovedInvestigational

    [T568] It is a pentasubstituted pyrrole [A177415] formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound. … [A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996.

    Mixtures: TIAZOMET ® A 40/10 TABLETAS, Atorvalan comp. 10 mg/5 mg-FilmtablettenProducts: VIATOR-A, ATORVASTATIN 1A PHAR 10MG
  8. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    This drug from BMS was not approved by the FDA due to angioedema safety concerns.

  9. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor. … Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

  10. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    It was first approved by the European Commission in January 2018. … [L40119] Rurioctocog alfa pegol is a covalent conjugate of [octocog alfa], which is a recombinant factor VIII produced by recombinant DNA technology from a Chinese hamster ovary cell line.

    Synonyms: Antihemophilic factor (recombinant), pegylated (20 kda)